We performed different subgroup analyses to evaluate possible influences of GLN daily dosage (greater than 0.3g/ kg/day versus less or equal than 0.3 g/kg/day), period of supple- mentation (more than 5 days versus less or equal than 5 days), severity of illness (APACHE II > 15 versus less or equal of 15), ITT data reporting, blindness, and quality of trials (Jadad score > 3 points versus